Literature DB >> 16762617

Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study.

Fernando S Velayos1, Edward V Loftus, Tine Jess, W Scott Harmsen, John Bida, Alan R Zinsmeister, William J Tremaine, William J Sandborn.   

Abstract

BACKGROUND & AIMS: Predictive and protective factors associated with colorectal cancer in chronic ulcerative colitis are not well described. Surveillance colonoscopy and 5-aminosalicylic acid therapy may mitigate cancer risk, but there is debate because these variables have not been evaluated in the same study. The presence of postinflammatory pseudopolyps and use of other anti-inflammatory medications may be important variables that influence risk, but data are sparse.
METHODS: Variables associated with colorectal cancer were registered in 188 patients with ulcerative colitis-related cancer and matched controls. Conditional logistic regression, adjusted for age at colitis diagnosis and colitis duration, identified a final set of variables independently associated with colorectal cancer.
RESULTS: In the final multiple variable model, the most important factors associated with colorectal cancer were a history of pseudopolyps (OR, 2.5; 95% CI: 1.4-4.6), 1 or 2 surveillance colonoscopies (OR, 0.4; 95% CI: 0.2-0.7), smoking (OR, 0.5; 95% CI: 0.2-0.9) and use of corticosteroids (OR, 0.4; 95% CI: 0.2-0.8), aspirin (OR, 0.3; 95% CI: 0.1-0.8), nonsteroidal anti-inflammatory drugs (OR, 0.1; 95% CI: 0.03-0.5), and 5-aminosalicylic acid agents (OR, 0.4; 95% CI: 0.2-0.9), although the latter was not statistically significant after 5 years. Primary sclerosing cholangitis and immunosuppressive use were not statistically significant.
CONCLUSIONS: These results suggest that, in a population matched for extent and duration of chronic ulcerative colitis, surveillance colonoscopy and use of anti-inflammatory medications may reduce the risk of colorectal cancer. A history of postinflammatory pseudopolyps appears to be a predictive factor for cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16762617     DOI: 10.1053/j.gastro.2006.03.028

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  90 in total

1.  Survival in elderly patients with ulcerative colitis and colorectal cancer.

Authors:  Wojciech Blonski; Gary R Lichtenstein
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

2.  Are we making progress in diagnosing and preventing gastrointestinal cancers?

Authors:  Jelle Haringsma; Nicoline C M van Heel; Ernst J Kuipers
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

Review 3.  Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.

Authors:  Srikanth Santhanam; David M Alvarado; Matthew A Ciorba
Journal:  Transl Res       Date:  2015-08-03       Impact factor: 7.012

Review 4.  Management of arthropathy in inflammatory bowel diseases.

Authors:  Rosario Peluso; Francesco Manguso; Maria Vitiello; Salvatore Iervolino; Matteo Nicola Dario Di Minno
Journal:  Ther Adv Chronic Dis       Date:  2015-03       Impact factor: 5.091

5.  Surveillance of dysplasia in inflammatory bowel disease: The gastroenterologist-pathologist partnership.

Authors:  David T Rubin; Jerrold R Turner
Journal:  Clin Gastroenterol Hepatol       Date:  2006-11       Impact factor: 11.382

6.  Mechanisms of colitis-accelerated colon carcinogenesis and its prevention with the combination of aspirin and curcumin: Transcriptomic analysis using RNA-seq.

Authors:  Yue Guo; Zheng-Yuan Su; Chengyue Zhang; John M Gaspar; Rui Wang; Ronald P Hart; Michael P Verzi; Ah-Ng Tony Kong
Journal:  Biochem Pharmacol       Date:  2017-03-04       Impact factor: 5.858

Review 7.  Precancer in ulcerative colitis: the role of the field effect and its clinical implications.

Authors:  Kathryn T Baker; Jesse J Salk; Teresa A Brentnall; Rosa Ana Risques
Journal:  Carcinogenesis       Date:  2018-01-12       Impact factor: 4.944

Review 8.  Colorectal Cancer in Inflammatory Bowel Disease.

Authors:  Ryan W Stidham; Peter D R Higgins
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

Review 9.  Colorectal cancer in inflammatory bowel disease: review of the evidence.

Authors:  D S Keller; A Windsor; R Cohen; M Chand
Journal:  Tech Coloproctol       Date:  2019-01-30       Impact factor: 3.781

Review 10.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.